Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 3, 2012, Pages 1557-1565

  Zode, Gulab S ^a,b   Bugge, Kevin E ^a,b   Mohan, Kabhilan ^c   Grozdanic, Sinisa D ^c   Peters, Joseph C ^b   Koehn, Demelza R ^b   Anderson, Michael G ^b   Kardon, Randy H ^b,c   Stone, Edwin M ^a,b   Sheffield, Val C ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; MYOCILIN; 4-PHENYLBUTYRIC ACID; ANTIINFECTIVE AGENT; ARYLBUTYRIC ACID DERIVATIVE; CYTOSKELETON PROTEIN; EYE DROPS; EYE PROTEIN; GLYCOPROTEIN; TRABECULAR MESHWORK-INDUCED GLUCOCORTICOID RESPONSE PROTEIN; TUNICAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAPHY; ENDOPLASMIC RETICULUM STRESS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MOUSE; NONHUMAN; OPEN ANGLE GLAUCOMA; PHENOTYPE; PRIORITY JOURNAL; RETINA GANGLION CELL; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TRABECULAR MESHWORK; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECT; EYE; FEMALE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MALE; METABOLISM;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTI-BACTERIAL AGENTS; AQUEOUS HUMOR; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; EYE; EYE PROTEINS; FEMALE; GLAUCOMA, OPEN-ANGLE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; MICE; MICE, TRANSGENIC; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PHENYLBUTYRATES; TUNICAMYCIN;

EID: 84860574268     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8837     Document Type: Article

References (47)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
2. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999;18:39-57.
3. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275:668-670.
4. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med. 2009;360:1113-1124.
5. Fingert JH, Stone EM, Sheffield VC, Alward WL. Myocilin glaucoma. Surv Ophthalmol. 2002;47:547-561.
6. Libby RT, Gould DB, Anderson MG, John SW. Complex genetics of glaucoma susceptibility. Annu Rev Genomics Hum Genet. 2005; 6:15-44.
7. Swiderski RE, Ross JL, Fingert JH, et al. Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization. Invest Ophthalmol Vis Sci. 2000;41:3420-3428.
8. Swiderski RE, Ying L, Cassell MD, Alward WL, Stone EM, Sheffield VC. Expression pattern and in situ localization of the mouse homologue of the human MYOC (GLC1A) gene in adult brain. Brain Res Mol Brain Res. 1999;68:64-72.
9. Tamm ER. Myocilin and glaucoma: facts and ideas. Prog Retin Eye Res. 2002;21:395-428.
10. Peters DM, Herbert K, Biddick B, Peterson JA. Myocilin binding to Hep II domain of fibronectin inhibits cell spreading and incorporation of paxillin into focal adhesions. Exp Cell Res. 2005;303:218-228.
11. Filla MS, Liu X, Nguyen TD, et al. In vitro localization of TIGR/ MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. Invest Ophthalmol Vis Sci. 2002;43:151-161.
12. Kim BS, Savinova OV, Reedy MV, et al. Targeted disruption of the myocilin gene (MYOC) suggests that human glaucoma-causing mutations are gain of function. Mol Cell Biol. 2001;21:7707-7713.
13. Liu Y, Vollrath D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum Mol Genet. 2004;13: 1193-1204.
14. Caballero M, Rowlette LL, Borras T. Altered secretion of a TIGR/ MYOC mutant lacking the olfactomedin domain. Biochim Biophys Acta. 2000;1502:447-460.
15. Jacobson N, Andrews M, Shepard AR, et al. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001;10:117-125.
16. Gould DB, Reedy M, Wilson LA, Smith RS, Johnson RL, John SW. Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma. Mol Cell Biol. 2006;26:8427-8436.
17. Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C. Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. Biochem Biophys Res Commun. 2003;312:592-600.
18. Borras T, Morozova TV, Heinsohn SL, Lyman RF, Mackay TF, Anholt RR. Transcription profiling in Drosophila eyes that overexpress the human glaucoma-associated trabecular meshwork-inducible glucocorticoid response protein/myocilin (TIGR/MYOC). Genetics. 2003;163:637-645.
19. Zode GS, Kuehn MH, Nishimura DY, et al. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest. 2011;121: 3542-3553.
20. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1996;1:117-125.
21. Gong B, Zhang LY, Lam DS, Pang CP, Yam GH. Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells. Mol Vis. 2010;16:997-1003.
22. Iordache C, Duszyk M. Sodium 4-phenylbutyrate upregulates ENaC and sodium absorption in T84 cells. Exp Cell Res. 2007;313:305-311.
23. Lee B, Rhead W, Diaz GA, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010;100:221-228.
24. Loffing J, Moyer BD, Reynolds D, Stanton BA. PBA increases CFTR expression but at high doses inhibits Cl(-) secretion in Calu-3 airway epithelial cells. Am J Physiol. 1999;277:L700-L708.
25. Ono K, Ikemoto M, Kawarabayashi T, et al. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord. 2009;15:649-654.
26. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
27. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol. 2004;66:899-908.
28. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology. 2009;34:1721-1732.
29. Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of deltaF508- CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics. 2008;7:1099-1110.
30. Bonapace G, Waheed A, Shah GN, Sly WS. Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad Sci U S A. 2004;101:12300-12305.
31. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A. 2000;97:1796-1801.
32. Anderson MG, Libby RT, Gould DB, Smith RS, John SW. High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma. Proc Natl Acad Sci U S A. 2005;102: 4566-4571.
33. Zode GS, Clark AF, Wordinger RJ. Bone morphogenetic protein 4 inhibits TGF-beta2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia. 2009;57:755-766.
34. Zode GS, Sethi A, Brun-Zinkernagel AM, Chang IF, Clark AF, Wordinger RJ. Transforming growth factor-beta2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. Mol Vis. 2011;17:1745-1758.
35. Yoshida H. ER stress and diseases. FEBS Lett. 2007;274:630-658.
36. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic. 2004;5:821-837.
37. Welch WJ, Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones. 1996;1:109-115.
38. Burns JN, Orwig SD, Harris JL, Watkins JD, Vollrath D, Lieberman RL. Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones. ACS Chem Biol. 2010;5:477-487.
39. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci. 2007;48:1683-1690.
40. McGuire BM, Zupanets IA, Lowe ME, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology. 2010:51:2077-2085.
41. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011;11:227-249.
42. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991;29:147-150.
43. Doh SH, Kim JH, Lee KM, Park HY, Park CK. Retinal ganglion cell death induced by endoplasmic reticulum stress in a chronic glaucoma model. Brain Res. 2010;1308:158-166.
44. Ito Y, Shimazawa M, Inokuchi Y, et al. Involvement of endoplasmic reticulum stress on neuronal cell death in the lateral geniculate nucleus in the monkey glaucoma model. Eur J Neurosci. 2011;33:843-855.
45. Carbone MA, Chen Y, Hughes GA, et al. Genes of the unfolded protein response pathway harbor risk alleles for primary open angle glaucoma. PLoS One. 2010;6:e20649.
46. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med. 1992; 327:569-570.
47. Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, Guggino WB. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004;16:204-211.